Bicocca Open Archive

Logo unimib boa
ROMERIO, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.921
NA - Nord America 2.615
AS - Asia 2.343
SA - Sud America 278
Continente sconosciuto - Info sul continente non disponibili 134
AF - Africa 53
OC - Oceania 27
Totale 11.371
Salva come PNG Salva come JPEG
Nazione #
SE - Svezia 3.759
US - Stati Uniti d'America 2.492
IT - Italia 1.144
SG - Singapore 561
VN - Vietnam 560
CN - Cina 377
DE - Germania 299
HK - Hong Kong 211
BR - Brasile 199
RU - Federazione Russa 173
IN - India 137
GB - Regno Unito 95
KR - Corea 95
FR - Francia 87
BD - Bangladesh 83
CA - Canada 78
NL - Olanda 66
JP - Giappone 57
ID - Indonesia 54
ES - Italia 53
PL - Polonia 43
IE - Irlanda 42
FI - Finlandia 35
PK - Pakistan 31
AR - Argentina 27
IR - Iran 27
AU - Australia 26
MX - Messico 23
BE - Belgio 22
IQ - Iraq 22
TR - Turchia 21
ZA - Sudafrica 21
DK - Danimarca 17
AT - Austria 14
CO - Colombia 14
SA - Arabia Saudita 14
UA - Ucraina 14
MY - Malesia 13
PH - Filippine 12
EC - Ecuador 11
CL - Cile 10
LT - Lituania 10
UZ - Uzbekistan 10
CH - Svizzera 9
MA - Marocco 8
PT - Portogallo 8
TW - Taiwan 8
IL - Israele 7
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
GR - Grecia 5
JO - Giordania 5
AL - Albania 4
EG - Egitto 4
ET - Etiopia 4
JM - Giamaica 4
KZ - Kazakistan 4
LB - Libano 4
NG - Nigeria 4
NP - Nepal 4
DO - Repubblica Dominicana 3
GA - Gabon 3
TN - Tunisia 3
AM - Armenia 2
BB - Barbados 2
EE - Estonia 2
GT - Guatemala 2
KE - Kenya 2
KH - Cambogia 2
MK - Macedonia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A1 - Anonimo 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
Totale 11.231
Salva come PNG Salva come JPEG
Città #
Stockholm 3.728
Milan 414
Singapore 337
Ashburn 325
Frankfurt am Main 252
San Jose 237
Ho Chi Minh City 184
Hong Kong 182
Hanoi 131
Council Bluffs 106
Los Angeles 98
Ann Arbor 90
Hefei 70
Washington 69
Rome 65
New York 61
Santa Clara 56
Beijing 53
Dallas 50
Seoul 50
Chicago 48
Jakarta 43
Columbus 42
Dublin 42
Tokyo 40
Boardman 36
Phoenix 33
São Paulo 33
Buffalo 32
Toronto 32
Turin 30
Amsterdam 28
Chandler 28
Florence 27
Jeju City 27
Bologna 25
Helsinki 22
Hyderabad 22
Shanghai 22
Houston 21
London 21
Naples 21
Atlanta 20
Figino 20
Maastricht 20
Brisbane 18
Philadelphia 18
Warsaw 18
Sassuolo 17
The Dalles 17
Can Tho 16
Da Nang 16
Orem 16
Chennai 15
Lauterbourg 15
Madison 15
New Delhi 15
Paris 15
Brooklyn 14
Johannesburg 14
Montreal 14
Brescia 13
Copenhagen 13
Denver 13
Ha Long 13
Biên Hòa 12
Monza 12
San Giuliano Terme 12
Seattle 12
Boston 11
Haiphong 11
Moscow 11
Baghdad 10
Hải Dương 10
Poplar 10
Tashkent 10
Kent 9
Lahore 9
Lappeenranta 9
Novate Milanese 9
Nuremberg 9
Parma 9
Vienna 9
Austin 8
Biloxi 8
Brussels 8
Cerdanyola del Vallès 8
Como 8
Desio 8
Medellín 8
Mexico City 8
Munich 8
Princeton 8
Quận Bình Thạnh 8
San Francisco 8
Barnet 7
Cedar Rapids 7
Guangzhou 7
Hangzhou 7
Huế 7
Totale 7.913
Salva come PNG Salva come JPEG
Nome #
Representative secondary PET micro and nanoplastics via ethylene glycol fragmentation (EGF): Physicochemical and immuno-toxicological properties 2.039
Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives 1.973
Synthesis and Biological Characterization of TLR4 Agonists as Innovative Vaccine Adjuvants 846
NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR 512
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists 429
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure 395
Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and in Vivo Activity 370
Potentiation of fluoroquinolone and macrolide activities by efflux pump inhibitory effect on Staphylococcus aureus and Streptococcus pyogenes of new benzyl piperazinyl lysine derivatives 350
Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview 347
New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants 325
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 314
Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists 306
Impact of Toll-like Receptor 4 (TLR4) chemical modulation by small- molecular antagonists in rare inflammatory-fibrotic diseases 305
Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists 298
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of Enterococcus faecium-binding Antibodies 268
Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant 253
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity 252
Cleaner synthesis of preclinically validated vaccine adjuvants 201
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection 193
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge 193
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 165
Functional impact of Toll-like Receptor 4 (TLR4) modulation in lung fibrosis-associated fibroblasts 159
Developing New Toll-Like Receptor 4 (TLR4) Modulators As Innovative And Inexpensive Vaccine Adjuvants 117
Design, Synthesis and Biological Evaluation of New Glycolipid-Based Toll-Like Receptor 4 (TLR4) Modulators 89
Developing New Toll-Like Receptor 4 (TLR4) Modulators as Innovative and Inexpensive Vaccine Adjuvants 86
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW, GLYCOLIPID-BASED TOLL-LIKE RECEPTOR 4 (TLR4) MODULATORS 79
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 72
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 63
NEW SMALL MOLECULES AS TLR4 MODULATORS: SYNTHESIS AND BIOLOGICAL CHARACTERIZATION 63
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 62
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 62
Harnessing Immunity: Synthesis of New Modulators of Toll-like Receptor 4 (TLR4) 39
HARNESSING IMMUNITY: SYNTHESIS OF NEW MODULATORS OF TOLL-LIKE RECEPTOR 4 (TLR4) 39
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 29
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 27
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 27
Design and synthesis of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy 24
Totale 11.371
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.830
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.830
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022118 0 0 0 0 0 0 0 28 14 12 16 48
2022/2023501 43 58 42 35 51 50 12 88 21 42 26 33
2023/2024536 52 19 39 31 52 65 44 23 53 42 42 74
2024/20251.451 70 89 120 101 104 76 77 64 131 194 148 277
2025/20267.530 557 251 225 404 320 164 392 184 346 4.197 155 335
2026/20271.235 207 201 512 315 0 0 0 0 0 0 0 0
Totale 11.371